Hans Hammers, MD, PhD

Articles

Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

March 15th 2023

Mehmet Asim Bilen, MD, presents a profile of a 65-year-old woman with metastatic renal cell carcinoma for discussion.

Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

March 15th 2023

Moshe Ornstein, MD, MA, starts a conversation on how patients with metastatic renal cell carcinoma are classified by risk, and how risk category influences approaches to systemic therapy.

Exciting Investigational Therapies in Advanced RCC

January 23rd 2023

The oncologists close their discussion with a look at some currently ongoing clinical trials in advanced renal cell carcinoma treatment.

Emerging Data in Non-Clear Cell RCC Treatment

January 16th 2023

Hans Hammers, MD, PhD, reviews emerging data on the challenging treatment of non-clear cell renal cell carcinoma.

COSMIC-313: Frontline Triplet Therapy in Advanced RCC

January 16th 2023

Experts discuss data from the COSMIC-313 study investigating a triplet combination therapy for the frontline treatment of advanced renal cell carcinoma.

Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial

January 9th 2023

Dr Moshe Orenstein reviews the 5-year data update of the CheckMate 214 trial in favorable risk subgroups of advanced renal cell carcinoma.

Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment

January 9th 2023

Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.

Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment

December 22nd 2022

Hans Hammers, MD, PhD, details his strategies for dosing lenvatinib in patients with advanced renal cell carcinoma.

Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

December 22nd 2022

Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.

Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC

December 15th 2022

Moshe Ornstein, MD, MA, explains his reasoning for starting patients with advanced renal cell carcinoma on an IO/IO combination regimen.

Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

December 15th 2022

Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.

Dr. Hammers on the Safety Profile of Lenvatinib/Pembrolizumab in RCC

August 20th 2021

Hans Hammers, MD, PhD,discusses the safety profile of lenvatinib in combination with pembrolizumab in renal cell carcinoma.

Dr. Hammers on the Potential Utility of HIF-2α Inhibitors in RCC

June 2nd 2021

Hans Hammers, MD, PhD, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma.

Dr. Hammers on the Importance of Assessing Quality of Life in RCC

May 12th 2021

Hans Hammers, MD, PhD, discusses the importance of assessing quality of life in renal cell carcinoma.

Dr. Hammers on the Efficacy of Lenvatinib/Pembrolizumab in Advanced RCC

April 5th 2021

Hans Hammers, MD, PhD, discusses the efficacy of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Dr. Hammers on Investigational Strategies to Inflame Tumors in RCC

October 28th 2020

Hans Hammers, MD, PhD, discusses investigational strategies that are being used to inflame tumors in renal cell carcinoma.

Dr. Hammers on Challenges With CAR T-Cell Therapy in RCC

September 16th 2019

Hans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with using CAR T-cell therapy in renal cell carcinoma.

Dr. Hammers on the Future of Immunotherapy in RCC

February 7th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of immunotherapy for patients with renal cell carcinoma (RCC).

Dr. Hammers on the Long-Term Benefits of the CheckMate-214 Study in RCC

January 11th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the long-term benefits of the CheckMate-214 study in patients with renal cell carcinoma (RCC).

Dr. Hammers on the CheckMate-214 Study for RCC

December 6th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the CheckMate-214 study for patients with renal cell carcinoma (RCC).